乳腺癌新辅助内分泌治疗对ER、PR、HER-2、Ki-67表达的影响

Neoadjuvant endocrine therapy for breast cancer and effects of ER,PR,HER-2,Ki-67 expression

目的新辅助内分泌治疗(Neoadjuvant endocrine therapy,NAET)在原发病灶和区域淋巴结降期,评价化疗敏感性,消除全身微转移灶等方面有其突出优越性,肿瘤组织中ER、PR、C-erb B-2、Ki-67的表达状态对于治疗方式选择及治疗效果预测有重要意义。方法通过对内蒙古医科大学附属人民医院收治符合条件的42例乳腺癌患者,施行新辅助内分泌治疗后行手术治疗并进行疗效评价,统计分析ER、PR、Her-2及Ki-67在新辅助内分泌治疗前后的表达变化情况。结果新辅助内分泌治疗后可降低ER、PR的阳性率(P值﹤0.05),对HER-2无明显影响(P值﹥0.05),可降低Ki-67的表达(P值﹤0.05)。结论新辅助内分泌治疗后总有效率为73.81%,使ER、PR的表达阴性率增加,对HER-2表达的影响不明显;可降低Ki-67的表达。

Objective Neoadjuvant endocrine therapy（Neoadjuvant endocrine therapy, NAET） in the primary lesion and regional lymph node down stage, the evaluation of chemotherapy sensitivity, eliminate body micro metastases has its prominent superiority, ER, PR in tumor tissues, C-erb B-2, the expression of Ki-67 state for the choice of treatment and treatment effect of prediction has an important significance. Methods this article through to the Inner Mongolia medical university affiliated people＇s hospital treated in accordance with conditions of 42 patients with breast cancer, a new adjuvant endocrine therapy after surgery treatment and curative effect evaluation, statistical analysis of ER, PR, its ehrs-2 and Ki-67 changes in the expression of before and after neoadjuvant endocrine therapy. Results after neoadjuvant endocrine therapy can reduce the positive rate of ER, PR value（P﹤0.05）, had no obvious effect on its ehrs-2（P﹥0.05）, can reduce the expression of Ki-67（P﹤0.05）. Conclusion the total effective rate was 73.81% after neoadjuvant endocrine therapy, increase the expression of ER and PR negative rate, the influence of the expression of its ehrs-2 is not obvious; Can reduce the expression of Ki-67.